|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics. CA Cancer J Clin. 56:106–130. 2006.
|
|
2
|
Oettle H and Neuhaus P: Adjuvant therapy
in pancreatic cancer: a critical appraisal. Drugs. 67:2293–2310.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Neoptolemos JP, Dunn JA, Stocken DD, et
al: Adjuvant chemoradiotherapy and chemotherapy in resectable
pancreatic cancer: a randomised controlled trial. Lancet.
358:1576–1585. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Neoptolemos JP, Stocken DD, Friess H, et
al: A randomized trial of chemoradiotherapy and chemotherapy after
resection of pancreatic cancer. N Engl J Med. 350:1200–1210. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Neoptolemos J, Büchler M, Stocken DD, et
al: ESPAC-3(v2): a multicenter, international, open-label,
randomized, controlled phase III trial of adjuvant
5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in
patients with resected pancreatic ductal adenocarcinoma. J Clin
Oncol. 27(suppl s18): abs LBA4505,. 2009.(ASCO Annual Meeting).
|
|
6
|
Andersson R, Aho U, Nilsson BI, et al:
Gemcitabine chemoresistance in pancreatic cancer: molecular
mechanisms and potential solutions. Scand J Gastroenterol.
44:782–786. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giovannetti E, del Tacca M, Mey V, et al:
Transcription analysis of human equilibrative nucleoside
transporter-1 predicts survival in pancreas cancer patients treated
with gemcitabine. Cancer Res. 66:3928–3935. 2006. View Article : Google Scholar
|
|
8
|
Ioka T, Ohkawa S, Yanagimoto H, et al:
Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1
versus gemcitabine (GEM) in unresectable advanced pancreatic cancer
(PC) in Japan and Taiwan: GEST study. J Clin Oncol. 29:2011.(ASCO
Annual Meeting).
|
|
9
|
Ichikawa W, Takahashi T, Suto K, et al:
Thymidylate synthase predictive power is overcome by irinotecan
combination therapy with S-1 for gastric cancer. Br J Cancer.
91:1245–1250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ichikawa W and Sasaki Y: Challenges in
predicting the clinical outcome in S-1-based chemotherapy for
gastric cancer patients. Int J Clin Oncol. 13:206–211. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kuramochi H, Hayashi K, Uchida K, et al:
High intratumoral dihydropyrimidine dehydrogenase mRNA levels in
pancreatic cancer associated with a high rate of response to S-1.
Cancer Chemother Pharmacol. 63:85–89. 2008. View Article : Google Scholar
|
|
12
|
Heid CA, Stevens J, Livak KJ and Williams
PM: Real time quantitative PCR. Genome Res. 6:986–994. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miyake K, Imura S, Yoshizumi T, Ikemoto T,
Morine Y and Shimada M: Role of thymidine phosphorylase and orotate
phosphoribosyltransferase mRNA expression and its ratio to
dihydropyrimidine dehydrogenase in the prognosis and
clinicopathological features of patients with pancreatic cancer.
Int J Clin Oncol. 12:111–119. 2007. View Article : Google Scholar
|
|
14
|
Mori K, Hasegawa M, Nishida M, et al:
Expression levels of thymidine phosphorylase and dihydropyrimidine
dehydrogenase in various human tumor tissues. Int J Oncol.
17:33–38. 2000.PubMed/NCBI
|
|
15
|
Ichikawa W: Prediction of clinical outcome
of fluoropyrimidine-based chemotherapy for gastric cancer patients,
in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer.
9:145–155. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Salonga D, Danenberg KD, Johnson M, et al:
Colorectal tumors responding to 5-fluorouracil have low gene
expression levels of dihydropyrimidine dehydrogenase, thymidylate
synthase, and thymidine phosphorylase. Clin Cancer Res.
6:1322–1327. 2000.
|
|
17
|
Takechi T, Fujioka A, Matsushima E and
Fukushima M: Enhancement of the antitumour activity of
5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase
activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human
tumour cells. Eur J Cancer. 38:1271–1277. 2002. View Article : Google Scholar
|
|
18
|
Neoptolemos JP, Stocken DD, Tudur Smith C,
et al: Adjuvant 5-fluorouracil and folinic acid vs observation for
pancreatic cancer: composite data from the ESPAC-1 and -3(v1)
trials. Br J Cancer. 100:246–250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Larsson SC, Hakansson N, Giovannucci E and
Wolk A: Folate intake and pancreatic cancer incidence: a
prospective study of Swedish women and men. J Natl Cancer Inst.
98:407–413. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakamoto E, Tsukioka S, Oie S, et al:
Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate
leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem
Biophys Res Commun. 365:801–807. 2008. View Article : Google Scholar
|
|
21
|
Tsukioka S, Uchida J, Tsujimoto H, et al:
Oral fluoropyrimidine S-1 combined with leucovorin is a promising
therapy for colorectal cancer: Evidence from a xenograft model of
folate-depleted mice. Mol Med Reports. 2:393–398. 2009.PubMed/NCBI
|
|
22
|
Cobo M, Isla D, Massuti B, et al:
Customizing cisplatin based on quantitative excision repair
cross-complementing 1 mRNA expression: a phase III trial in
non-small-cell lung cancer. J Clin Oncol. 25:2747–2754. 2007.
View Article : Google Scholar : PubMed/NCBI
|
